Market Overview:
The global neutrophil elastase inhibitor market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of respiratory diseases, bronchiectasis, and acute myelocytic leukemia (AML). In addition, the increasing demand for novel therapies for treating these diseases is also contributing to the growth of this market. The global neutrophil elastase inhibitor market can be segmented on the basis of type into brevenal, CHF-6333, dociparstat sodium, KRP-109, POL-6014 and others. On the basis of application, this market can be segmented into respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis; bronchiectasis; and acute myelocytic leukemia (AML). This market can also be segmented on the basis of region into North America, Latin America Europe Asia Pacific and Middle East & Africa.
Product Definition:
A neutrophil elastase inhibitor is a drug that blocks the action of neutrophil elastase, an enzyme released by white blood cells that can damage tissues. Neutrophil elastase inhibitors are used to treat conditions such as cystic fibrosis and chronic obstructive pulmonary disease (COPD), in which excess neutrophil elastase activity can cause damage to the lungs.
Brevenal:
Brevenal (chlorambucil) is a chemotherapy medication used to treat chronic inflammatory and autoimmune diseases. It works by blocking the action of certain enzymes that cause inflammation. Brevenal has been approved by the FDA for treatment of acute lymphoblastic leukemia, but it is not approved for use in patients with cancer who have taken it more than once or within 28 days before their surgery.
CHF-6333:
CHF-6333 is a novel, non-steroidal anti-inflammatory drug currently in phase II clinical trials. It is being investigated for the treatment of patients with chronic inflammatory conditions such as rheumatoid arthritis and Crohn's disease. CHF-6333 has shown efficacy in both animal models and human cells exposed to the drug at nanomolar concentrations; however, it has not been studied extensively due to its unavailability as a commercial compound.
Application Insights:
Neutrophil elastase inhibitor finds application in the treatment of respiratory diseases, which include asthma and COPD. The global prevalence of these conditions is high; around 40-50 million people are affected by them. In addition, COPD is a major cause of disability and death worldwide. According to estimates reported in the Global Burden of Disease Study, a joint project by the Institute for Health Metrics and Evaluation (IHME) at Harvard University and the World Health Organization (WHO), around 60-80%of total deaths occur due to this disease across all age groups globally every year.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of companies coupled with high R&D investment and commercialization of products for treating respiratory diseases is expected to drive the regional market over the forecast period. In addition, increasing prevalence of asthma and COPD is also anticipated to boost product demand in North America during the forecast period.
Asia Pacific region is estimated to witness lucrative growth over the next eight years owing to rising healthcare expenditure, growing awareness about treatment options for various diseases, increase in disposable income levels along with an increase in life expectancy are some factors responsible for driving this regional market at a significant CAGR from 2018 to 2030 The Middle East & Africa region has been witnessing an outbreak of COVID-19 disease since April 2019 which spread across several countries including Saudi Arabia, UAE, Egypt among others have resulted into huge economic losses as well as human lives due to lack treatment facilities This has compelled international organizations like WHO.
Growth Factors:
- Increasing incidence of respiratory diseases: The increasing incidence of respiratory diseases is one of the key growth drivers for the global neutrophil elastase inhibitor market. This is because, patients with respiratory diseases are at a higher risk of developing lung inflammation and other associated complications, which can be effectively treated with NE inhibitors.
- Growing awareness about the benefits of NE inhibitors: There is a growing awareness among physicians and patients about the benefits of using NE inhibitors for treating various respiratory disorders. This is likely to boost demand for these drugs in the coming years.
- Rising R&D investments by pharmaceutical companies: Pharmaceutical companies are investing heavily in R&D to develop novel therapies that can target different types of pulmonary disorders. This is expected to result in increased availability of effective and safe NE inhibitors in the near future, driving market growth further.
Scope Of The Report
Report Attributes
Report Details
Report Title
Neutrophil Elastase Inhibitator Market Research Report
By Type
Brevenal, CHF-6333, Dociparstat Sodium, KRP-109, POL-6014, Others
By Application
Respiratory, Bronchiectasis, Acute Myelocytic Leukemia, Others
By Companies
AstraZeneca Plc, Cantex Pharmaceuticals Inc, Chiesi Farmaceutici SpA, Kyorin Pharmaceutical Co Ltd, Polyphor Ltd, AstraZeneca Plc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
226
Number of Tables & Figures
159
Customization Available
Yes, the report can be customized as per your need.
Global Neutrophil Elastase Inhibitator Market Report Segments:
The global Neutrophil Elastase Inhibitator market is segmented on the basis of:
Types
Brevenal, CHF-6333, Dociparstat Sodium, KRP-109, POL-6014, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Respiratory, Bronchiectasis, Acute Myelocytic Leukemia, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca Plc
- Cantex Pharmaceuticals Inc
- Chiesi Farmaceutici SpA
- Kyorin Pharmaceutical Co Ltd
- Polyphor Ltd
- AstraZeneca Plc
Highlights of The Neutrophil Elastase Inhibitator Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Brevenal
- CHF-6333
- Dociparstat Sodium
- KRP-109
- POL-6014
- Others
- By Application:
- Respiratory
- Bronchiectasis
- Acute Myelocytic Leukemia
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neutrophil Elastase Inhibitator Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neutrophil elastase inhibitor is a drug that inhibits the enzyme neutrophil elastase. Neutrophil elastase is responsible for breaking down proteins in the body, which can lead to inflammation and tissue damage. By inhibiting this enzyme, neuterphile elastase inhibitors may help to reduce the risk of these conditions.
Some of the major players in the neutrophil elastase inhibitator market are AstraZeneca Plc, Cantex Pharmaceuticals Inc, Chiesi Farmaceutici SpA, Kyorin Pharmaceutical Co Ltd, Polyphor Ltd, AstraZeneca Plc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Neutrophil Elastase Inhibitator Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Neutrophil Elastase Inhibitator Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Neutrophil Elastase Inhibitator Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Neutrophil Elastase Inhibitator Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Neutrophil Elastase Inhibitator Market Size & Forecast, 2020-2028
4.5.1 Neutrophil Elastase Inhibitator Market Size and Y-o-Y Growth
4.5.2 Neutrophil Elastase Inhibitator Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Brevenal
5.2.2 CHF-6333
5.2.3 Dociparstat Sodium
5.2.4 KRP-109
5.2.5 POL-6014
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Respiratory
6.2.2 Bronchiectasis
6.2.3 Acute Myelocytic Leukemia
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Neutrophil Elastase Inhibitator Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Neutrophil Elastase Inhibitator Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Brevenal
9.6.2 CHF-6333
9.6.3 Dociparstat Sodium
9.6.4 KRP-109
9.6.5 POL-6014
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Respiratory
9.10.2 Bronchiectasis
9.10.3 Acute Myelocytic Leukemia
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Brevenal
10.6.2 CHF-6333
10.6.3 Dociparstat Sodium
10.6.4 KRP-109
10.6.5 POL-6014
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Respiratory
10.10.2 Bronchiectasis
10.10.3 Acute Myelocytic Leukemia
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Brevenal
11.6.2 CHF-6333
11.6.3 Dociparstat Sodium
11.6.4 KRP-109
11.6.5 POL-6014
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Respiratory
11.10.2 Bronchiectasis
11.10.3 Acute Myelocytic Leukemia
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Brevenal
12.6.2 CHF-6333
12.6.3 Dociparstat Sodium
12.6.4 KRP-109
12.6.5 POL-6014
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Respiratory
12.10.2 Bronchiectasis
12.10.3 Acute Myelocytic Leukemia
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Brevenal
13.6.2 CHF-6333
13.6.3 Dociparstat Sodium
13.6.4 KRP-109
13.6.5 POL-6014
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Respiratory
13.10.2 Bronchiectasis
13.10.3 Acute Myelocytic Leukemia
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Neutrophil Elastase Inhibitator Market: Competitive Dashboard
14.2 Global Neutrophil Elastase Inhibitator Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca Plc
14.3.2 Cantex Pharmaceuticals Inc
14.3.3 Chiesi Farmaceutici SpA
14.3.4 Kyorin Pharmaceutical Co Ltd
14.3.5 Polyphor Ltd
14.3.6 AstraZeneca Plc
